Head-To-Head Contrast: Rezolute (NASDAQ:RZLT) & BetterLife Pharma (OTCMKTS:PVOTF)

Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Institutional & Insider Ownership

83.0% of Rezolute shares are held by institutional investors. 18.4% of Rezolute shares are held by company insiders. Comparatively, 34.8% of BetterLife Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Rezolute and BetterLife Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	0	0	8	0	3.00
BetterLife Pharma	0	0	0	0	0.00

Rezolute currently has a consensus target price of $24.13, indicating a potential upside of 491.30%. Given Rezolute’s stronger consensus rating and higher probable upside, research analysts plainly believe Rezolute is more favorable than BetterLife Pharma.

Profitability

This table compares Rezolute and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-69.83%	-62.16%
BetterLife Pharma	N/A	-205.15%	-147.23%

Earnings and Valuation

This table compares Rezolute and BetterLife Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$68.46 million	($1.27)	-3.21
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A

Summary

Rezolute beats BetterLife Pharma on 6 of the 9 factors compared between the two stocks.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.